Quest Diagnostics (DGX) Liabilities and Shareholders Equity (2009 - 2026)

Quest Diagnostics has reported Liabilities and Shareholders Equity for 18 years, with the latest figure at $16.9 billion in Q2 2026.

• Quarterly Liabilities and Shareholders Equity rose 6.07% year-over-year to $16.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $66.0 billion (up 3.16% YoY) and the FY2025 annual result came in at $16.2 billion, changed 0.45% from the prior year.
• Liabilities and Shareholders Equity rose to $16.9 billion in Q2 2026 per DGX's latest filing, from $16.7 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $16.9 billion in Q2 2026 and troughed at $12.8 billion in Q1 2023.
• A 5-year average of $14.7 billion and a median of $14.0 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity retreated 5.69% in 2022, then advanced 19.38% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $12.8 billion in 2022, then grew by 9.23% to $14.0 billion in 2023, then increased by 15.2% to $16.2 billion in 2024, then gained by 0.45% to $16.2 billion in 2025, then rose by 4.4% to $16.9 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $16.9 billion, $16.7 billion, and $16.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.